Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Aug
06
Today In Oncology
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
Combination Regimen Prolongs PFS in dMMR-MSI-H Metastatic Colorectal Cancer
CKM Syndrome Associated With Increased, Stage-Specific Cancer Risk, Study Finds
Population-Based MGUS Screening Enables Earlier Detection of Multiple Myeloma Without Increasing Psychological Distress
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo